[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335940-105":59,"doc-detail-335940-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","vaccines-targeting-esr1-activating-mutations-elicit-anti-tumor-immune-responses-and-suppress-estrogen-signaling-in-therapy-resistant-er-breast-cancer","Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer","","ER+ breast cancers rely on high estrogen receptor alpha (ESR1) expression and signaling, making them responsive to anti-endocrine therapy. However, prolonged treatment commonly leads to endocrine resistance as gain-of-function mutations arise in ESR1. This study developed recombinant vaccines encoding multiple ESR1 activating mutant forms (ESR1mut), confirmed ESR1-specific T cell responses, and tested anti-tumor activity using ESR1mut-expressing murine mammary cancer models. Vaccination suppressed tumor growth, ESR1mut expression, and estrogen signaling in vivo. Human peptide presentation was shown by HPLC using ER+ BC cell MHC complexes, and human T cells recognizing ESR1mut epitopes were detected in an ER+ BC patient.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/vaccines-targeting-esr1-activating-mutations-elicit-anti-tumor-immune-responses-and-suppress-estrogen-signaling-in-therapy-resistant-er-breast-cancer/335940/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/vaccines-targeting-esr1-activating-mutations-elicit-anti-tumor-immune-responses-and-suppress-estrogen-signaling-in-therapy-resistant-er-breast-cancer/335940.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are ESR1 activating mutations important in endocrine-resistant ER+ breast cancer?","Question",{"text":112,"@type":113},"They drive ligand-independent ESR signaling through clustered gain-of-function mutations in the ESR1 ligand-binding domain, enabling neomorphic pathway activation that supports acquired resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study evaluate with ESR1mut recombinant vaccines?",{"text":117,"@type":113},"It assessed whether vaccines encoding several ESR1 activating mutant forms could elicit ESR1-specific T cell responses and suppress tumor growth, ESR1mut expression, and estrogen signaling in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"How was immune targeting relevance supported for human ER+ breast cancer?",{"text":121,"@type":113},"The work used HPLC to demonstrate presentation of ESR1 and ESR1mut peptides on human ER+ breast cancer cell MHC complexes and detected human T cells reactive to ESR1mut epitopes in an ER+ breast cancer patient.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335940,1790805307,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","BRIEF REPORT  \nVaccines targeting ESR1 activating mutations elicit anti-tumor immune responsesand suppress estrogen signaling in therapy resistant ER+ breast cancer  \nGabrielle P. Daileya, Christopher A. Rabiolaa, Gangjun Leia, Junping Weia, Xiao-Yi Yanga, Tao Wanga, Cong-Xiao Liua, Melissa Gajdaa, Amy C. Hobeikaa, Amanda Summersa, Robert D. Mareka, Michael A. Morseb, Herbert K. Lyerlya,c,d, Erika J. Crosbya,d, and Zachary C. Hartman a,c,d  \naDepartment of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USA; bDepartment of Medicine, Duke University, Durham, NC, USA; cDepartment of Pathology, Duke University, Durham, NC, USA; dDepartment of Integrative Immunobiology, Duke University, Durham, NC, USA  \nABSTRACT  \nER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, which can occur through the emergence of gain-of-function mutations in ESR1 . The central importance of ESR1 and development of mutated forms of ESR1 suggest that vaccines targeting these proteins could potentially be effective in preventing or treating endocrine resistance. To explore the potential of this approach, we developed several recombinant vaccines encoding different mutant forms of ESR1 (ESR1mut) and validated their ability to elicit ESR1-specific T cell responses. We then developed novel ESR1mut-expressing murine mammary cancer models to test the anti-tumor potential of ESR1mut vaccines. We found that these vaccines could suppress tumor growth, ESR1mut expression and estrogen signaling in vivo. To illustrate the applicability of these findings, we utilize HPLC to demonstrate the presentation of ESR1 and ESR1mut peptides on human ER+ BC cell MHC complexes. We then show the presence of human T cells reactive to ESR1mut epitopes in an ER+ BC patient. These findings support the development of ESR1mut vaccines, which we are testing in a Phase I clinical trial.  \nARTICLE HISTORY  \nReceived 13 September 2023 Revised 5 January 2024 Accepted 19 January 2024  \nKEYWORDS  \nBreast cancer; estrogen receptor; neoepitopes; resistance mutations; cancer vaccines; preventative vaccination; immunotherapy  \nIntroduction  \nApproximately 75% of breast cancers (BC) are estrogen receptor α+ (ER+) and treated with anti-estrogen (endocrine) therapies, such as tamoxifen and aromatase inhibitors. While these therapies are often highly effective, ~25% of patients with localized cancers (Stage I–III) and nearly all with metastatic cancers (Stage IV) develop resistance to these therapies. 1–7 A common resistance mechanism in these heavily treated patients occurs through gain-of-function mutations in ESR1, found in 20–40% of patients with metastatic ER+ BC who received endocrine therapies, but rarely in primary tumors.5,8,9 These gain-of-function mutations are clustered within the ligand-binding domain (LBD) of ESR1 at one of three neighboring amino acids, all of which lead to ligandindependent ER activity and neomorphic activation of various pathways as a major mechanism of acquired endocrine resistance.1,8, 10–12  \nESR1 is highly expressed in ER+ breast cancer and its mutations cause amino acid alterations, which generate potential neoantigens that can be recognized and targeted immunologically. Neoantigens are formed by mutations to self-proteins that render them immunologically non-self, which many studies have suggested to be a central factor in generating antitumor immunity. 13, 14 While most neoantigens are formed by  \nrandomly occurring mutations, 14 emergence of ESR1 activating mutations in ER+ BC after prolonged endocrine therapy occurs in a predictable manner as a mechanism of therapeutic resistance. In addition to their ligand-independent estrogen signaling, studies have also documented that mutated ESR1 confers neomorphic on","cbCaigNb7uogLynm","https://ap.wps.com/l/cbCaigNb7uogLynm","pdf",3835632,"English","# Abstract\n# Introduction\n# Therapeutic rationale for ESR1mut targeting\n# Vaccine design and immune responses\n# Evidence for anti-tumor effects and antigen presentation\n# Clinical translation and trial context","[{\"question\":\"Why are ESR1 activating mutations important in endocrine-resistant ER+ breast cancer?\",\"answer\":\"They drive ligand-independent ESR signaling through clustered gain-of-function mutations in the ESR1 ligand-binding domain, enabling neomorphic pathway activation that supports acquired resistance.\"},{\"question\":\"What did the study evaluate with ESR1mut recombinant vaccines?\",\"answer\":\"It assessed whether vaccines encoding several ESR1 activating mutant forms could elicit ESR1-specific T cell responses and suppress tumor growth, ESR1mut expression, and estrogen signaling in vivo.\"},{\"question\":\"How was immune targeting relevance supported for human ER+ breast cancer?\",\"answer\":\"The work used HPLC to demonstrate presentation of ESR1 and ESR1mut peptides on human ER+ breast cancer cell MHC complexes and detected human T cells reactive to ESR1mut epitopes in an ER+ breast cancer patient.\"}]","Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer | PDF",1790012881,25]